Literature DB >> 29279341

Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).

Gerald Chi1, Megan K Yee1, Alpesh N Amin2, Samuel Z Goldhaber3, Adrian F Hernandez4, Russell D Hull5, Alexander T Cohen6, Robert A Harrington7, C Michael Gibson8.   

Abstract

Entities:  

Keywords:  anticoagulants; factor Xa inhibitors; hospitalization; venous thromboembolism; venous thrombosis

Mesh：

Substances：

Year:  2018        PMID： 29279341     DOI： 10.1161/CIRCULATIONAHA.117.031187

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  8 in total

Review 1.  Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.

Authors:  Kayla M Miller; Michael J Brenner
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

2.  Is there a role for low-dose DOACs as prophylaxis?

Authors:  Alexander T Cohen; Beverley J Hunt
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

3.  Pharmacological properties of betrixaban.

Authors:  Menno V Huisman; Frederikus A Klok
Journal:  Eur Heart J Suppl       Date:  2018-05-09       Impact factor: 1.803

4.  Highlights: burden of venous thromboembolism and role of extended-duration thromboprophylaxis in acute medically ill patients.

Authors: 
Journal:  Eur Heart J Suppl       Date:  2018-05-09       Impact factor: 1.803

5.  Betrixaban for prevention of venous thromboembolism in acute medically ill patients.

Authors:  Jan Beyer-Westendorf; Peter Verhamme; Rupert Bauersachs
Journal:  Eur Heart J Suppl       Date:  2018-05-09       Impact factor: 1.803

6.  Influence of the duration of hospital length of stay on frequency of prophylaxis and risk for venous thromboembolism among patients hospitalized for acute medical illnesses in the USA.

Authors:  Alpesh Amin; W Richey Neuman; Melissa Lingohr-Smith; Brandy Menges; Jay Lin
Journal:  Drugs Context       Date:  2019-01-21

7.  Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals.

Authors:  Anne-Céline Martin; Wei Huang; Samuel Z Goldhaber; Russell D Hull; Adrian F Hernandez; Charles-Michael Gibson; Frederick A Anderson; Alexander T Cohen
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

Review 8.  Current Opinion on the use of Direct Oral Anticoagulants for the Prophylaxis of Venous Thromboembolism among Medical Inpatients.

Authors:  Jane J Lee; Sahar Memar Montazerin; Fahimehalsadat Shojaei; Gerald Chi
Journal:  Ther Clin Risk Manag       Date:  2021-05-26       Impact factor: 2.423
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.